{
    "nct_id": "NCT03415126",
    "official_title": "A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Written informed consent obtained prior to any study-related procedure being performed;\n* Male or non-pregnant, non-lactating female patient at least 18 years of age at the time of consent;\n* Eastern Cooperative Oncology Group Performance Status 0-1 (Part A) and PS 0-2 (Part B)\n* Histologically or cytologically confirmed\n* advanced or metastatic solid tumor (Part A)\n* Group 1: BRAF mutant melanoma (Part B)\n* Group 2: NRAS or HRAS mutant solid tumors(Part B)\n* Group 3: KRAS mutant CRC.(Part B)\n* Group 4: KRAS mutant NSCLC (Part B)\n* Group 5: Pancreatic Ductal Adenocarcinoma (Part B)\n* Progressive disease after failure of or intolerant to all available standard systemic treatments that have shown a documented benefit in overall survival for their respective tumor type.\n* Measurable or evaluable disease per RECIST v1.1\n* Screening hematology values of the following:\n* absolute neutrophil count ≥ 1000/μL,\n* platelets ≥ 100,000/μL,\n* hemoglobin ≥ 9 g/dL\n* Screening chemistry values of the following:\n* alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3.0 × upper limit of the normal (ULN),\n* total bilirubin ≤ 1.5 × ULN,\n* creatinine ≤ 1.5 × ULN,,\n* albumin ≥ 2.8 g/dL.\n* Screening heart function lab test\n* creatinine kinase - MB, troponin-I, and troponin-T within normal limits\n* Subject is willing and able to comply with all protocol required visits and assessments, including biopsy if assigned.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with ASN007 or another ERK1/2 inhibitor\n* Known hypersensitivity to ASN007 or its excipients;\n* Part B: Prior treatment with a RAF or MEK pathway inhibitor, except BRAFmutant melanoma (Group 1)\n* Prior chemotherapy, targeted therapy or monoclonal antibody therapy within 3 weeks of start of study treatment (Day1), or 5 half-lives, whichever is shorter.\n* Concurrent or prior bone marrow factors (e.g. G-CSF, GM-CSF or erythropoietin) within 3 weeks prior to Day 1 of treatment.\n* Febrile neutropenia or serious persistent infection within 2 weeks prior to Day 1 of treatment\n* Failure to recover from major surgery or traumatic injury within 4 weeks or minor surgery within 2 weeks prior to Day 1 of treatment.\n* History of or current evidence / risk of retinal vein occlusion (RVO) central serous retinopathy (CSR), or glaucoma with intraocular pressures ≥ 21 mmHg or other pre-existing ocular conditions that may put the patient at risk for ocular toxicities\n* Known central nervous system (CNS) primary tumor, CNS metastases or carcinomatous meningitis (Part A). Patients may be enrolled with CNS metastasis in certain circumstances in Part B.\n* Clinically significant heart disorders including an ejection fraction of < 50%\n* Other serious uncontrolled conditions such as fungal, bacterial or viral infection; HIV, Hepatitis B or C, bleeding disorders, interstitial lung disease,\n* Any other condition that might place the patient at undue risk.",
    "miscellaneous_criteria": ""
}